The AAPS Journal

, Volume 12, Issue 2, pp 109–116

Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant

  • Vinay Saluja
  • Jean P. Amorij
  • Maarten L. van Roosmalen
  • Kees Leenhouts
  • Anke Huckriede
  • Wouter L. J. Hinrichs
  • Henderik W. Frijlink
Research Article

DOI: 10.1208/s12248-009-9168-2

Cite this article as:
Saluja, V., Amorij, J.P., van Roosmalen, M.L. et al. AAPS J (2010) 12: 109. doi:10.1208/s12248-009-9168-2

Abstract

Nasal administration of influenza vaccine has the potential to facilitate influenza control and prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines only generate systemic and mucosal immune responses if strong adjuvants are used, which are often associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n. vaccination with subunit influenza vaccine in mice. It is shown that simple admixing of the vaccine with the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n. delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n. administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n. influenza immunization.

Key words

influenza vaccineintranasal vaccineLactococcus lactis GEM particles

Copyright information

© The Author(s) 2009

Authors and Affiliations

  • Vinay Saluja
    • 1
  • Jean P. Amorij
    • 1
    • 4
  • Maarten L. van Roosmalen
    • 2
  • Kees Leenhouts
    • 2
  • Anke Huckriede
    • 3
  • Wouter L. J. Hinrichs
    • 1
  • Henderik W. Frijlink
    • 1
  1. 1.Department of Pharmaceutical Technology and BiopharmacyUniversity of GroningenGroningenThe Netherlands
  2. 2.Mucosis BVGroningenThe Netherlands
  3. 3.Department of Medical Microbiology, Molecular Virology Section, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
  4. 4.Research and Development UnitThe Netherlands Vaccine InstituteBilthovenThe Netherlands